

Please type a plus sign, (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number	09/707,738
Filing Date	November 6, 2000
First Named Inventor	Sette, Alessandro
Group Art Unit	1645-1644
Examiner Name	Not Assigned DeClomp
Attorney Docket Number	018623-006250US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
AP	1	5,114,713		Sinigaglia	05/19/92	---
	2	5,196,512		Bianchi, et al.	03/23/93	---
	3	5,336,758		Berzofsky, et al.	08/09/94	---
	4	5,679,640		Gaeta, et al.	10/31/97	---
	5	5,736,142		Sette, et al.	04/07/98	---
	6	5,785,973		Bixler, et al.	07/26/98	---

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
AD	7	EPO	0 534 615 A2		Vitiello, et al.	03/31/93	---	
	8	WIPO	WO 92/02543		Gaeta, et al.	02/20/92	---	
	9	WIPO	WO 93/05011		Cottens, et al.	03/16/93	---	
	10	WIPO	WO 94/20127		Grey, et al.	09/15/94	---	
	11	WIPO	WO 95/07707		Sette, et al.	03/23/95	---	

Examiner
Signature

Ann DeClomp

Date
Considered

2-5-03

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ See attached Kinds of U.S. Patent Documents. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1276184 v1

Please type a plus sign (+) inside this box

+

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Complete if Known

Application Number 09/707,738
Filing Date November 6, 2000
First Named Inventor Sette, Alessandro
Group Art Unit 1645-1644
Examiner Name Not Assigned De Clouy
Attorney Docket Number 018623-006250US

TECH CENTER 1600/2940
OCT 9 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ov	12	ALEXANDER, et al., "Development of High Potency Universal DR-Restricted Helper Epitopes by Modification of High Affinity DR-Blocking Peptides"; <i>Immunity</i> Vol. 1, 751-761 (Dec. 1994)	
	13	BARTOLONI, et al., "Immunogenicity of meningococcal B polysaccharide conjugated to tetanus toxoid or CRM197 via adipic acid dihydrazide"; <i>Vaccine</i> Vol. 13, No. 5, pp. 463-470 (1995)	
	14	BIXLER, et al., "Synthetic Peptide Representing a T-cell Epitope of CRM197 Substitutes as Carrier Molecule in a Haemophilus Influenzae Type B (Hib) Conjugate Vaccine"; <i>Adv. Exp. Med. Biol.</i> 251: 175-180, (1989)	
	15	BORRAS-CUESTA et al., "Engineering of Immunogenic Peptides by Co-Linear Synthesis of Determinants Recognized by B and T Cells," <i>Eur. J. Immunol.</i> Vol. 17:1213-1215 (1987)	
	16	BRETT et al., "Fine Specificity of T Cell Recognition of the Same Peptide in Association With Different I-A Molecules," <i>Journal of Immunology</i> , Vol. 143 No. 3 771-779 (Aug. 1989)	
	17	BROWN, et al., "Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1"; <i>Nature</i> , Vol. 364, 33-39, (July 1993)	
	18	BUSCH, et al., "Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces"; <i>International Immunology</i> , Vol. 2, No. 5 443-451 (1990)	
	19	CHONG, et al., "A Strategy for Rational Design of Fully Synthetic Glycopeptide Conjugate Vaccines"; <i>Infection and Immunity</i> , Vol. 65, No. 12 4918-4925, (December 1997)	
	20	CHU, et al., "Further Studies on the Immunogenicity of Haemophilus influenzae Type b and Pneumococcal Type 6A Polysaccharide-Protein Conjugates"; <i>Infection and Immunity</i> , Vol. 40, No. 1, 245-256 (April, 1983)	
	21	CLARKE et al., "Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein," <i>Nature</i> , Vol. 330, 381-384 (November 1987)	
	22	DiGeorge et al., "Immune Responses of Seven Different 'Promiscuous' T-Cell Epitopes on Chimeric Peptide Vaccine Design," <i>Peptide Vaccines and Immunology</i> , pp 732-733, The Ohio State University, Columbus, OH 43210	
	23	FERN et al., "Promiscuous Malaria Peptide Epitope Stimulates CD45Ra T Cells From Peripheral Blood of Nonexposed Donors," <i>Journal of Immunology</i> , Vol. 148:907-913 (1992)	
	24	FERRARI et al., "Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen," <i>J. Clin. Invest.</i> Vol. 88:214-222 pp. 168-170 (July 1991)	
	25	FRANCIS et al., "Non-Responsiveness to a Foot-and-Mouth Disease Virus Peptide Overcome by Addition of Foreign Helper T-Cell Determinants," <i>Nature</i> , Vol. 330 (Nov. 1987)	
	26	FRANKE, et al., "Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites"; <i>Vaccine</i> , 17: 1201-1205 (1999)	

Examiner Signature *Am De Clouy* Date Considered 2-5-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1276184 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 3 of 4

Complete if Known

Applicati n Number	09/707,738
Filing Date	November 6, 2000
First Named Inventor	Sette, Alessandro
Group Art Unit	1645-1644
Examiner Name	Not Assigned <i>DL</i>
Attorney Docket Number	018623-006250US

RECEIVED
OCT 09 2001
CHIEF OF CENTER 1600/2900



OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>AD</i>	27	GREENSTEIN et al., "A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific for HIV pp120," Journal of Immunology Vol. 148:3970-3977 No. 12 (June 1992)	
	28	HERVAS-STUBBS, et al. "Overcoming class II-linked non-responsiveness to hepatitis B vaccine"; Vaccine Vol. 12, No. 10, (1994) pp 867-871	
	29	HILL, et al., "Conformational and Structural characteristics of Peptides Binding to HLA-DR Molecules"; The Journal of Immunology, Vol. 147, No. 1, 189-197 (July 1991)	
	30	HO et al., "Identification of Two Promiscuous T Cell Epitopes from Tetanus Toxin", Eur. J. Immunol. Vol. 20:477-483 (1990)	
	31	ISHIOKA, et al. "MHC Interaction and T Cell Recognition of Carbohydrates and Glycopeptides"; The Journal of Immunology Vol. 148 No. 8, pp. 2446-2451 (April 1992)	
	32	ISHIOKA, et al. "Major histocompatibility complex class II association and induction of T cell responses by carbohydrates and glycopeptides"; Springer Semin. Immunopathol. 15:293-302 (1993)	
	33	KAUMAYA et al., "Immunogenicity and Antigenicity of a Promiscuous T-Cell Epitope and a Topographic B-Cell Determinant of the Protein Antigen LDH-C4," Peptides Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium June 16-21, 1991, Cambridge, Massachusetts, pp883-885	
	34	KAUMAYA et al., "A Universal HTLV-I Template Vaccine Incorporating Cytotoxic, Neutralizing and Promiscuous Epitope," Peptides, Vaccines and Immunology, pp 712-714 The Ohio State University, Columbus, OH 43210.	
	35	KRIEGER, et al., "Single Amino Acid Changes in DR and Antigen Define Residues Critical for Peptide-MHC Binding and T Cell Recognition"; The Journal of Immunology, Vol. 146, No. 7, 2331-2340 (April 1991)	
	36	LETT, et al., "Immunogenicity of Polysaccharides Conjugated to Peptides Containing T- and B-cell Epitopes"; Infection and Immunity Vol. 62, No. 3, 785-792, (March 1994)	
	37	MEISTER et al., "Two Novel T Cell Epitope Prediction Algorithms Based on MHC-Binding Motifs; Comparison of Predicted and Published Epitopes from Mycobacterium tuberculosis and HIV Protein Sequences," Vaccine Vol 13(6):581-591 (1995)	
	38	MILICH et al., "Antibody Production to the Nucleocapsid and Envelope of the Hepatitis B Virus Primed by a Single Synthetic T Cell Site" Nature Vol. 329 pp. 547-549 (Oct 1987)	
	39	O'SULLIVAN et al., "Characterization of the Specificity of Peptide Binding To Four Dr Haplotypes," Journal of Immunology Vol. 145:1799-1808 (Sept 1990)	
	40	O'SULLIVAN, et al., "Truncation Analysis of Several DR Binding Epitopes"; The Journal of Immunology, Vol. 146, No. 4, 1240-1246 (February 1991)	
<i>✓</i>	41	O'SULLIVAN et al., "On the Interaction of Promiscuous Antigenic Peptides with Different Dr Alleles," Journal of Immunology Vol. 147:2663-2669 (Oct. 1991)	

Examiner
Signature

am Delle...

Date
Considered

2-5-03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1276184 v1

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Complete if Known

Applicati n Numb r	09/707,738
Filing Dat	November 6, 2000
First Nam d Invent r	Sette, Alessandro
Group Art Unit	1645 1644
Examiner Name	Not Assigned - Dr. Chung
Attorney Docket Number	018623-006250US

TECH CENTER 1600/2900

OCT 09 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Dr	42	PANINA-BORDIGNON, et al., "Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells"; Eur. J. Immunol. 19: 2237-2242 (1989)	
	43	PARTIDOS et al., "Prediction and Identification of a T Cell Epitope in the Fusion Protein of Measles Virus Immunodominant in Mice and Humans," Journal of General Virology Vol. 71:2099-2105 (1990)	
	44	POWELL, et al., "Peptide Stability in Drug Development. II. Effect of Single Amino Acid Substitution and Glycosylation on Peptide Reactivity in Human Serum"; Pharmaceutical Research, Vol. 10, No. 9, 1268-1273 (1993)	
	45	ROCHE, et al., "High-Affinity Binding of an Influenza Hemagglutinin-Derived Peptide to Purified HLA-DR"; The Journal of Immunology, Vol. 144, No. 5, 1849-1856 (March 1990)	
	46	SINIGAGLIA et al., "A Malaria T-Cell Epitope Recognized in Association with Most Mouse and Human MHC Class II Molecules," Nature Vol. 336:22/29 (Dec 1988)	
	47	SOUTHWOOD, et al., "Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires", The Journal of Immunology, 160: 3363-3373 (1998)	
	48	STAGG et al., "Primary Human T-Cell Responses to the Major Outer Membrane Protein of Chlamydia trachomatis," Immunology Vol. 79:1-9 (1993)	
	49	WANG et al., "Directionality in 'promiscuous' T-Cell Epitope Selection on Colinear B- and T-Cell Constructs," Peptide Vaccines and Immunology, pp. 753-754, The Ohio State University, Columbus, OH 43210	

Examiner Signature	<i>Am D. Bone</i>	Date Considered	2-5-03
-----------------------	-------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1276184 v1